Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214005 · ClinicalTrials.gov registry record · Phase 2
Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls
A Phase 2 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01214005 is a Phase 2 study that has completed, run by Brown University. The registered enrollment target is 60 participants.
The verdict
NCT01214005, a Phase 2 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This project tests two hypotheses concerning the low smoking cessation rates in smokers with schizophrenia. The first hypothesis is that smokers with schizophrenia experience stronger and more sustained effects of smoking abstinence on negative mood and smoking urge than control smokers without psychiatric illness. The second hypothesis is that smokers with schizophrenia experience stronger reinforcing effects of a smoking lapse (i.e., more rewarding effects of smoking after a period of abstinence) than control smokers without psychiatric illness.
Interventions
- BEHAVIORAL smoking abstinence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214005
The ClinicalTrials.gov registry entry for NCT01214005 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which smoking abstinence is the first listed.
NCT01214005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214005 about?
NCT01214005 is a clinical study titled "Smoking Abstinence and Lapse Effects in Smokers With Schizophrenia and Controls". This project tests two hypotheses concerning the low smoking cessation rates in smokers with schizophrenia. The first hypothesis is that smokers with schizophrenia experience stronger and more sustained effects of smoking abstinence on negative mood and smoking urge than control smokers without psyc...
What is the current status of trial NCT01214005?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2009-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01214005?
The interventions under investigation include: smoking abstinence (BEHAVIORAL).
Who is sponsoring clinical trial NCT01214005?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.